You are here

Clinical Trials: Cord Blood


Body: Condition:   Cerebral Palsy
Interventions:   Biological: Autologous Stem Cells;   Other: Saline Infusion (Placebo)
Sponsors:   The University of Texas Health Science Center, Houston;   Cord Blood Registry, Inc.;   Let's Cure CP Foundation;   Mission Connect, a program of TIRR Foundation
Active, not recruiting - verified June 2017
Body: Condition:   Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor
Intervention:   Other: Cord Blood Transplantation
Sponsor:   Assistance Publique - Hôpitaux de Paris
Body: Conditions:   Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions:   Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
Sponsor:   University of Pittsburgh
Recruiting - verified March 2017
Body: Conditions:   EBV;   CMV;   Adenovirus
Interventions:   Drug: CTL for CMV seropositive donors;   Drug: CTL for CMV naïve donors
Sponsor:   Catherine Bollard
Recruiting - verified May 2017
Body: Conditions:   Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions:   Other: Treg-enriched infusion;   Drug: Interleukin-2
Sponsors:   Dana-Farber Cancer Institute;   Miltenyi Biotec GmbH;   Prometheus Laboratories;   National Cancer Institute (NCI)
Recruiting - verified July 2017
Body: Conditions:   Single Umbilical Cord Blood Transplantation;   Non-myeloablative Conditioning;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia
Intervention:   Drug: HSC835
Sponsor:   Novartis Pharmaceuticals
Completed - verified July 2017
Body: Condition:   Blood And Marrow Transplantation
Intervention:   Drug: Eltrombopag
Sponsors:   M.D. Anderson Cancer Center;   Novartis Pharmaceuticals
Recruiting - verified April 2017
Body: Conditions:   CMV;   EBV;   Adenovirus Infections
Intervention:   Drug: Cytotoxic T lymphocytes (CTLs).
Sponsors:   Children's Research Institute;   M.D. Anderson Cancer Center
Body: Condition:   Bronchopulmonary Dysplasia
Interventions:   Biological: Pneumostem®;   Biological: normal saline
Sponsor:   Medipost Co Ltd.
Recruiting - verified April 2017
Body: Condition:   Hypoplastic Left Heart Syndrome
Intervention:   Biological: autologous cell-based delivery
Sponsors:   Timothy J. Nelson;   University of Oklahoma;   Children's Hospital of Philadelphia
Recruiting - verified June 2017
Body: Conditions:   GATA2;   Immunodeficiency;   MDS
Interventions:   Procedure: Allogeneic HSC;   Drug: Busulfan Test dose;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine Anti-Thymocyte Globulin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified January 31, 2017
Body: Conditions:   Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome (MDS);   Lymphoma
Intervention:   Procedure: Cord Blood Units
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   National Institute of Allergy and Infectious Diseases (NIAID);   National Cord Blood Program, New York Blood Center
Recruiting - verified January 12, 2017
Body: Condition:   Hypoplastic Left Heart Syndrome (HLHS)
Intervention:   Other: Collection of umbilical cord blood
Sponsor:   Mayo Clinic
Body: Condition:   Bronchopulmonary Dysplasia
Interventions:   Biological: Pneumostem®;   Other: Normal Saline
Sponsor:   Medipost Co Ltd.
Completed - verified April 2017
Body: Condition:   Leukemia
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Alloreactive NK infusion;   Drug: Interleukin-2;   Procedure: Stem Cell Infusion;   Drug: G-CSF;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas;   CML Program Project Grant
Recruiting - verified June 2017